PACAP27 induces migraine-like attacks in migraine patients

@article{Ghanizada2019PACAP27IM,
  title={PACAP27 induces migraine-like attacks in migraine patients},
  author={Hashmat Ghanizada and Mohammad Al-Mahdi Al-Karagholi and Nanna Arngrim and Jes Olesen and Messoud Ashina},
  journal={Cephalalgia},
  year={2019},
  volume={40},
  pages={57 - 67}
}
Introduction Pituitary adenylate cyclase-activating polypeptide (PACAP) is found in two functional isoforms, namely PACAP38 and PACAP27. The migraine-inducing properties of PACAP38 are well studied. However, it is not known whether the lesser-known and under-studied protein isoform, PACAP27, can also induce migraine attacks. Here, we studied the effect of human PACAP27 infusion on induction of migraine in a provocation model. Methods In a crossover study, 20 migraine without aura patients were… 
Effect of Adrenomedullin on Migraine-Like Attacks in Patients With Migraine
TLDR
It is found that patients reported in a period of 0 to 12 hours stronger headache intensity after adrenomedullin compared to placebo infusion, which suggests that adrenomed Mullin or its receptors are novel therapeutic targets for the treatment of migraine.
Targeting pituitary adenylate cyclase-activating polypeptide (PACAP) with monoclonal antibodies in migraine prevention: a brief review
TLDR
The evidence of the role of PACAP in migraine pathophysiology and the first clinical trials in migraine prophylaxis with monoclonal antibodies AMG 301 and ALD1910 which act against PAC1 and PACAP38 respectively are discussed and critically evaluated.
Early treatment with sumatriptan prevents PACAP38-induced migraine: A randomised clinical trial
TLDR
It is suggested that sumatriptan prevents PACAP38-induced migraine by modulation of nociceptive transmission within the trigeminovascular system.
Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache
TLDR
The findings suggest that ketorolac and sumatriptan attenuated PACAP38-induced headache in healthy volunteers without vascular effects.
Effect of pituitary adenylate cyclase-activating polypeptide-27 on cerebral hemodynamics in healthy volunteers: A 3T MRI study
TLDR
Pituitary adenylate cyclase-activating polypeptide (PACAP) has emerged as an important signaling peptide in migraine pathogenesis and post hoc analysis of PACAP38 data compared with PACAP27 showed that PACAP isoforms dilates MMA with significantly different magnitude.
Targets for migraine treatment: beyond calcitonin gene-related peptide
TLDR
Following positive phase-III clinical trials, lasmiditan is the first ditan to be FDA-approved and PACAP has experimental evidence suggesting a role in migraine pathophysiology, and the presence of PACAP in key migraine structures along with positive provocative tests for both PACAP-38 andPACAP-27 indicate this pathway may still be a pharmacological target.
Two-hour infusion of vasoactive intestinal polypeptide induces delayed headache and extracranial vasodilation in healthy volunteers
TLDR
Continuous intravenous infusion of VIP over 2 h induced a long-lasting cranial vasodilation, activation of the cranial parasympathetic system, and delayed mild headaches in healthy volunteers.
Cellular distribution of PACAP-38 and PACAP receptors in the rat brain: Relation to migraine activated regions
TLDR
The findings suggest that the rich supply of PACAP-38 and PAC1 receptors is associated with basic functional responses in the central nervous system (CNS), and there are important close anatomical relations with calcitonin gene-related peptide in CNS regions associated with migraine pathophysiology.
Targeting BKCa Channels in Migraine: Rationale and Perspectives
TLDR
Clinical studies on BKCa channel openers or blockers in migraine patients are needed because there is a high affinity and a close coupling between BK Ca channels and ATP-sensitive potassium (KATP) channels, the role of which has recently been established in migraine pathophysiology.
PACAP induces light aversion in mice by an inheritable mechanism independent of CGRP
TLDR
It is proposed that CGRP and PACAP act by independent convergent pathways that cause a migraine-like symptom in mice and suggests that PACAP-targeted drugs may be effective in patients who do not respond to C GRP-based therapeutics.
...
1
2
3
...

References

SHOWING 1-10 OF 49 REFERENCES
PACAP38 induces migraine-like attacks in patients with migraine without aura.
TLDR
Pituitary adenylate cyclase activating peptide-38 infusion caused headache and vasodilatation in both healthy subjects and migraine patients and caused delayed migraine-like attacks in migraine sufferers.
PACAP38 dose-response pilot study in migraine patients
TLDR
It is suggested that 10 pmol/kg/min PACAP38 is the most optimal dose to induce migraine-like attacks.
Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38.
TLDR
PACAP38 has a much higher affinity for thePAC1 receptor and it is suggested that migraine induction by PACAP38 may be because of activation of the PAC1 receptor, which may be a future anti-migraine drug target.
Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine
TLDR
CGRP did not induce PS, whereasPACAP38 induced PS in 48% of patients, however, CGRP and PACAP38 did not induced more PS in patients who developed an attack compared with those who did not develop an attack.
Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase.
TLDR
It is suggested that intracellular cyclic AMP accumulation plays a crucial role in migraine induction and is a further step in the understanding of the intrACEllular pathway of migraine initiation.
Effect of the H1-antihistamine clemastine on PACAP38 induced migraine
TLDR
H1-antihistamine, clemastine, failed to prevent migraine or headache after pituitary adenylate cyclase activating peptide-38 infusion, thus making a role for histamine release or mast cell degranulation in pituitaries' induced migraine less likely.
Vasoactive Intestinal Peptide Causes Marked Cephalic Vasodilation, but does not Induce Migraine
TLDR
VIP mediates a marked dilation of cranial arteries, but does not trigger migraine attacks in migraineurs, providing further evidence against a purely vascular origin of migraine.
Targeted Pituitary Adenylate Cyclase-Activating Peptide Therapies for Migraine
TLDR
The selective affinity of PACAP38 to the PAC1 receptor makes this receptor a highly interesting and potential novel target for migraine treatment and effectiveness of antagonism of this receptor should be investigated in randomized clinical trials.
PACAP and its receptors in cranial arteries and mast cells
TLDR
It is suggested that PACAP1–38 might induce migraine via degranulation of dural mast cells via a yet unknown receptor.
Dural mast cell degranulation is a putative mechanism for headache induced by PACAP-38
TLDR
The hypothesis that mast cell degranulation is involved in PACAP-induced migraine is supported by findings that correlate with clinical studies and are caused by a difference in efficacy on phospholipase C.
...
1
2
3
4
5
...